Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2004
Conference Publication
Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimen
Mills, AK, Gibbs, S, Keane, C, Mollee, P, Grimmett, K, Van Kuilenburg, R, Saal, R, Gill, D, Prince, HM, Seymour, JF and Marlton, P (2004). Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimen. 46th Annual Meeting of the American-Society-of-Hematology, San Diego Ca, Dec 04-07, 2004. WASHINGTON: AMER SOC HEMATOLOGY.
2004
Journal Article
Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia
Mollee, P., Gupta, V., Song, K., Reddy, V., Califaretti, N., Tsang, R., Crump, M. and Keating, A. (2004). Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia. Bone Marrow Transplantation, 33 (12), 1201-1208. doi: 10.1038/sj.bmt.1704506
2004
Conference Publication
Serum free light chain ratios do not detect relapse in some patients with intact immunoglobulin myeloma post autologous peripheral blood stem cell transplantation.
Tate, JR, Mollee, P and Gill, D (2004). Serum free light chain ratios do not detect relapse in some patients with intact immunoglobulin myeloma post autologous peripheral blood stem cell transplantation.. 56th Annual Meeting of the American-Association-for-Clinical-Chemistry, Los Angeles Ca, Jul 25-29, 2004. WASHINGTON: AMER ASSOC CLINICAL CHEMISTRY.
2004
Journal Article
Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome
Mollee, P. N., Wechalekar, A. D., Pereira, D. L., Franke, N., Reece, D., Chen, C. and Stewart, A. K. (2004). Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplantation, 33 (3), 271-277. doi: 10.1038/sj.bmt.1704344
2004
Journal Article
Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia
Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., Wolf, M., Gibson, J., Schwarer, A. P., Spencer, A., Browett, P., Hawkins, T., Seldon, M., Herrmann, R. and Watson, A. (2004). Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of Oncology, 15 (12), 1810-1815. doi: 10.1093/annonc/mdh468
2003
Conference Publication
The impact of the hyper-CVAD chemotherapy regimen on the ability to mobilize peripheral blood stem cells (PBSC) in patients with hematological malignancies.
Mollee, PN, Mills, AK, Grimmett, K, Van Kuilenburg, R, Saal, RJ, Gill, D, Cobcroft, R and Marlton, P (2003). The impact of the hyper-CVAD chemotherapy regimen on the ability to mobilize peripheral blood stem cells (PBSC) in patients with hematological malignancies.. 45th Annual Meeting of the American-Society-of-Hematology, San Diego, CA, United States, 6-9 December 2003. Washington, DC, United States: American Society of Hematology.
2003
Journal Article
Measurement of immunoglobulin free light chains in serum - Reply
Tate, JR, Mollee, P and Gill, D (2003). Measurement of immunoglobulin free light chains in serum - Reply. Clinical Chemistry, 49 (11), 1958-1958. doi: 10.1373/clinchem.2003.026294
2003
Journal Article
Why aren’t we performing more allografts for aggressive non-Hodgkin’s lymphoma?
Mollee, P., Lararus, H. M. and Lipton, J. (2003). Why aren’t we performing more allografts for aggressive non-Hodgkin’s lymphoma?. Bone Marrow Transplantation, 31 (11), 953-960. doi: 10.1038/sj.bmt.1704040
2003
Journal Article
Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype
Song, Kevin W., Mollee, Peter, Keating, Amanda and Crump, Michael (2003). Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. British Journal of Haematology, 120 (6), 978-985. doi: 10.1046/j.1365-2141.2003.04203.x
2002
Conference Publication
Effect of gemcitabine, dexamethasone and cisplatin salvage chemotherapy (GDP) on peripheral blood stem cell (PBSC) mobilization in patients with lymphoma.
Mollee, P, Nagy, T, Saragosa, R, Turner, R, Keating, A and Crump, M (2002). Effect of gemcitabine, dexamethasone and cisplatin salvage chemotherapy (GDP) on peripheral blood stem cell (PBSC) mobilization in patients with lymphoma.. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002. WASHINGTON: AMER SOC HEMATOLOGY.
2002
Conference Publication
Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).
Mollee, P, Gupta, V, Song, K, Tsang, R, Crump, M and Keating, A (2002). Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002.
2002
Conference Publication
Autologous stem cell transplantation (ASCT) for relapsed/refractory follicular large cell lymphoma (FLCL).
Mollee, P, Song, K, Keating, A, Tsang, R and Crump, M (2002). Autologous stem cell transplantation (ASCT) for relapsed/refractory follicular large cell lymphoma (FLCL).. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002. WASHINGTON: AMER SOC HEMATOLOGY.
2002
Journal Article
Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma
Song, KW, Mollee, P, Patterson, B, Brien, W and Crump, M (2002). Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. British Journal of Haematology, 119 (1), 125-127. doi: 10.1046/j.1365-2141.2002.03778.x
2002
Journal Article
Progenitor cell mobilisation - Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma
Mollee, P, Pereira, D, Nagy, T, Song, K, Saragosa, R, Keating, A and Crump, M (2002). Progenitor cell mobilisation - Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplantation, 30 (5), 273-278. doi: 10.1038/sj.bmt.1703653
2002
Conference Publication
Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia
Durrant, S, Szer, J, Bradstock, K, Nivison-Smith, I and Mollee, P (2002). Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia. 23rd Annual Scientific Meeting of the Transplantation-Society-of-Australia-and-New-Zealand, Canberra Australia, May 11-13, 2005. LONDON: NATURE PUBLISHING GROUP.
2001
Conference Publication
Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.
Keating, A, Filshie, R, Mollee, P and Wang, XH (2001). Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.. WASHINGTON: AMER SOC HEMATOLOGY.
2001
Journal Article
Single institution outcomes of treatment of severe aplastic anaemia
Mollee, P., Woodward, N., Durrant, S., Lockwood, L., Gillett, E. A., Morton, J. and Rowell, J. (2001). Single institution outcomes of treatment of severe aplastic anaemia. Internal Medicine Journal, 31 (6), 337-342. doi: 10.1046/j.1445-5994.2001.00078.x
2001
Journal Article
Single institution outcomes of treatment of severe aplastic anaemia
Mollee, P., Woodward, N., Durrant, S., Lockwood, L., Gillett, E. A., Morton, J. and Rowell, J. (2001). Single institution outcomes of treatment of severe aplastic anaemia. Internal Medicine Journal, 31 (6), 337-342. doi: 10.1046/j.1445-5994.2001.00078.x
2001
Conference Publication
Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation
Irving, I, Williamson, J, Mollee, P, Morton, AJ, Sloots, T, Siebert, D and Durrant, S (2001). Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation. BASINGSTOKE: NATURE PUBLISHING GROUP.
2001
Conference Publication
Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.
Durrant, S., Irving, I., Mollee, P., Morton, A. J., Webb, M. and Macfarlane, D. (2001). Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.. 27th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, United Kingdom: Nature Publishing Group.
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: